ArticleESMO gastrointestinal oncology2026
Patterns of presentation and diagnostic delays in biliary tract cancers: a real-world European study.
Article in ESMO gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Biliary tract cancers (BTCs) often present late due to nonspecific symptoms and a lack of effective population screening. We characterised diagnostic routes, symptom-to-diagnosis intervals, and their relationship with stage and outcomes across three European centres. Materials and methods: We conducted a retrospective observational study of consecutive patients diagnosed with BTC assessed by medical oncology from 1 June 2022 to 31 January 2024 in Spain, Slovenia, and Italy. Demographics, presenting symptoms, route of diagnosis, investigations, treatments, and outcomes were extracted from electronic medical records. Survival was assessed using Kaplan-Meier analysis and Cox regression. The study was approved by local ethics committees. Results: Eighty-six patients were included [Spain 59 (68.6%), Slovenia 16 (18.6%), and Italy 11 (12.8%)]; the median age was 71 years (range 40-96); and 65.1% were male. Tumour types included intrahepatic cholangiocarcinoma (41.9%), distal cholangiocarcinoma (23.3%), gallbladder (12.8%), ampullary (11.6%), and perihilar cholangiocarcinoma (9.3%). Presentation routes included: primary care (46.5%), the emergency department (45.3%), and incidental (8.1%). The median time from symptom onset to diagnosis was 2.56 months [95% confidence interval (CI) 1.78-3.09], which was longer with primary care (versus emergency department) (4.13 months versus 1.37 months, Conclusion: BTC continues to be diagnosed at advanced stages and is frequently associated with diagnostic delays, often presenting with nonspecific symptoms. Strengthening referral pathways and improving early recognition of warning signs, particularly in primary care, may help optimise diagnostic processes and should be further evaluated in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.